PMA device
Vivistim System
Mobia Medical, Inc. · Stimulator, Autonomic Nerve, Implanted For Stroke Rehabilitation (QPY, Class III) · First FDA decision Aug 27, 2021, newest Apr 24, 2025Stroke recovery and rehabilitation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
Breakthrough-designated
Device trials
7
Naming "Vivistim"
MAUDE reports
74
Brand "Vivistim", since 2015
PubMed studies
9
Mentioning "Vivistim"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Vivistim System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- Vivistim SystemPMA supplement
P210007-S005 · Decided Apr 24, 2025 · 51 days after receipt · Normal 180 Day Track No User Fee
Device type: Stimulator, autonomic nerve, implanted for stroke rehabilitation (QPY) · Physical Medicine & Rehabilitation
- Vivistim® SystemPMA supplement
P210007-S002 · Decided Mar 25, 2024 · 62 days after receipt · Normal 180 Day Track
Device type: Stimulator, autonomic nerve, implanted for stroke rehabilitation (QPY) · Physical Medicine & Rehabilitation
- Vivistim® SystemBreakthroughPMA
P210007 · Decided Aug 27, 2021 · 178 days after receipt
Device type: Stimulator, autonomic nerve, implanted for stroke rehabilitation (QPY) · Physical Medicine & Rehabilitation
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Phrenic Nerve StimulatorNational determinationOn the books160.19Updated Jun 12, 2020
- Transcutaneous Electrical Nerve Stimulators (TENS)Local determinationIn effectL33802CGS Administrators, LLCUpdated Dec 7, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Vivistim", any status and sponsor, newest update first.
MicroTransponder Inc.Not on our public-company list
NCT05301140 · 1,000 participants (planned) · Start Mar 15, 2023 · Primary completion Dec 31, 2028
Device: Vivistim System · For: Upper Extremity Problem
Sites: Orlando, Florida; Elk Grove Village, Illinois; Evanston, Illinois · 16 sites in all
State University of New York at BuffaloAcademic, hospital or other
NCT07643337 · 24 participants (planned) · Start Jun 2026 · Primary completion Dec 15, 2027
Device: Vagus Nerve Stimulation Therapy · For: Upper Limb Deficit; Stroke Gait Rehabilitation; Stroke
Sites: Buffalo, New York
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT05694663 · 40 participants (planned) · Start Oct 9, 2024 · Primary completion Feb 2028
Device: Vivistim · For: Chronic Ischemic Stroke
Sites: New York, New York
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Vivistim", and for the whole product code for context.
This brand
74 reports: 4 malfunction, 70 injury, 0 death
Whole product code QPY
74 reports: 4 malfunction, 70 injury, 0 death
Newest reports for this brand
3012309950-2026-00059 · Received Oct 27, 2026 · Event dated Sep 23, 2026
Device type: Stimulator, Autonomic Nerve, Implanted For Stroke Rehabilitation (QPY)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Dysphagia/ Odynophagia; Voice alteration
3012309950-2026-00058 · Received Oct 25, 2026 · Event dated Sep 1, 2026
Device type: Stimulator, Autonomic Nerve, Implanted For Stroke Rehabilitation (QPY)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Impaired Healing
3012309950-2026-00056 · Received Oct 23, 2026 · Event dated Sep 4, 2026
Device type: Stimulator, Autonomic Nerve, Implanted For Stroke Rehabilitation (QPY)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hemorrhage/Blood Loss/Bleeding
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Vivistim"[tiab]. The summary above synthesizes these.
- Vagus nerve stimulation: Potential for treating chronic wounds.
Budhiraja A, Mehta A, Alhamo MA, et al. · Wound Repair Regen · 2024
- Vagus nerve stimulation paired with rehabilitation for stroke: Implantation experience from the VNS-REHAB trial.
Liu CY, Russin J, Adelson DP, et al. · J Clin Neurosci · 2022Randomized Controlled Trial
- Vagus nerve stimulation paired with rehabilitation for post-stroke recovery: A single center experience of patient satisfaction and outcomes.
Roy JM, Musmar B, Ritz C, et al. · Clin Neurol Neurosurg · 2025
- Safety of Paired Vagus Nerve Stimulation Implantation in the Presence of a Cardiac Pacemaker: A Case Report.
Adelson PD, Schmid A · Neurosurg Pract · 2025Case Reports
- Upper extremity motor outcomes during paired vagus nerve stimulation in chronic ischemic stroke: a retrospective single-health-system cohort study.
Benitez R, Darling M, Zaorski P, et al. · Front Neurol · 2026Observational Study
- Vagus Nerve Stimulation Paired With Rehabilitation in the Home Environment for People With Chronic Post-Stroke Upper Limb Deficits (VNS-REHAB At-Home): Protocol for a Feasibility Trial.
Doherty SJ, Patel R, Spinelli-Guglielmo L, et al. · Adv Rehabil Sci Pract · 2025
- Study protocol for the Vivistim GRASP registry: capturing real-world outcomes of paired vagus nerve stimulation in the chronic stroke population.
Doherty SJ, Prudente CN, Adham Hinds R, et al. · Front Stroke · 2026
- Implementation and results of paired vagus nerve stimulation (Vivistim) program for neurorestoration following ischemic stroke: A single-center experience.
Nwankwo AK, Patil SN, Nelson MC, et al. · Surg Neurol Int · 2026
- Vagus Nerve Stimulation Paired With Upper Extremity Rehabilitation for Chronic Stroke: Real-World Implementation and Outcomes.
Saylor A, Patrick L, Reddy CG, et al. · Arch Rehabil Res Clin Transl · 2026Review
Other devices of this type
Also filed under product code QPY.
- Vivistim® Paired VNS SystemMobia Medical, Inc. · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.